Cannabis Bioscience International Holdings, Inc. (CBIH) intrinsic value & 10-year financials
Cannabis Bioscience International Holdings, Inc. (CBIH) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue shrank 2.2% a year to $303.0K, with an average return on invested capital of 149.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $1.6M
- Revenue (FY2025)
- $303.0K
- Revenue growth (4-yr CAGR)
- -2.2%
- ROIC (10-yr avg)
- 149.7%
- Free cash flow (FY2025)
- —
CBIH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $303.0K | -$548.8K | -$0.00 | — | -139.1% | 63.9% |
| FY2024 | $248.8K | -$651.3K | -$0.00 | — | -195.4% | 84.9% |
| FY2023 | $316.8K | -$1.0M | -$0.00 | — | -310.4% | 300.2% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cannabis Bioscience International Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cannabis Bioscience International Holdings, Inc. has earned high returns on invested capital, averaging 50.6% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Cannabis Bioscience International Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cannabis Bioscience International Holdings, Inc. is modeled at -2.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.00 per share.